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ABSTRACT
Friedreich’s ataxia (FRDA) is an untreatable disor-
der with neuro- and cardio-degenerative progres-
sion. This monogenic disease is caused by the
hyper-expansion of naturally occurring GAA repeats
in the first intron of the FXN gene, encoding for
frataxin, a protein implicated in the biogenesis of
iron-sulfur clusters. As the genetic defect interferes
with FXN transcription, FRDA patients express a nor-
mal frataxin protein but at insufficient levels. Thus,
current therapeutic strategies are mostly aimed to
restore physiological FXN expression. We have pre-
viously described SINEUPs, natural and synthetic
antisense long non-coding RNAs, which promote
translation of partially overlapping mRNAs through
the activity of an embedded SINEB2 domain. Here,
by in vitro screening, we have identified a number
of SINEUPs targeting human FXN mRNA and capa-
ble to up-regulate frataxin protein to physiological
amounts acting at the post-transcriptional level. Fur-
thermore, FXN-specific SINEUPs promote the recov-
ery of disease-associated mitochondrial aconitase
defects in FRDA-derived cells. In summary, we pro-
vide evidence that SINEUPs may be the first gene-
specific therapeutic approach to activate FXN trans-
lation in FRDA and, more broadly, a novel scalable
platform to develop new RNA-based therapies for
haploinsufficient diseases.
INTRODUCTION
Friedreich’s ataxia (FRDA) is a life-threatening monogenic
disease with neuro- and cardio-degenerative progression
(1). It represents the most frequent type of inherited ataxia,
affecting >15 000 patients in Europe and North America.
Patients typically show degeneration of large sensory neu-
rons of the dorsal root ganglia, of Betz pyramidal neu-
rons of the cerebral cortex and lateral cortico-spinal and
spinocerebellar tracts, as well as lesions in the dentate nu-
cleus of the cerebellum (2). In addition, non-neurological
degeneration causes hypertrophic cardiomyopathy and in-
creased incidence of diabetes mellitus. Neurodegenerative
motor symptoms typically appear before adolescence with
progressive gait instability and loss of coordination, while
the cardiac component of the disease causes premature
mortality at a mean age of 40 years (3). Almost all FRDA
patients carry an intronic homozygous expansion of natu-
ral GAA repeats located in the frataxin (FXN) gene (4). The
human FXN locus contains normally from 10 to 66 GAA-
triplet repeats within the first intron, whereas FRDA indi-
viduals have a hyper-expansion of such repeats, up to 1700
triplets. In a small percentage of cases, however, patients are
compound heterozygotes for GAA expansion on one FXN
allele and a second allele with a small insertion, deletion
or point mutation in FXN open reading frame (5). Longer
hyper-expansions result in a more severe phenotype with an
earlier onset and faster progression (6,7). GAA repeat ex-
pansions impair FXN transcription by inducing the forma-
tion of triple helical DNA structures (sticky DNA) (8), per-
sistent DNA/RNAhybrids (R-loops) (9) and specific epige-
netic modifications (10,11). The FXN gene encodes for the
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precursor of frataxin, a small iron-binding protein, that is
mainly, but not exclusively, confined inside the mitochon-
drial matrix (12–14), where it is converted into the func-
tional mature form (15). Although its primary function is
still debated (16), mature frataxin is a key component of the
Iron-Sulfur Cluster (ISC) biosynthetic apparatus (17–20),
which provides the essential cofactor to all ISC-dependent
enzymes of the cell (21,22). As consequence of insufficient
FXN expression, defective ISC biosynthesis triggers a se-
ries of vicious cycles leading to deregulated intracellular
iron homeostasis, impaired mitochondrial electron trans-
port chain and higher sensitivity to trigger oxidant- and
stress-induced cell death (23–25).
Currently, there are no therapies to treat the disease or
prevent its progression. The most promising approaches
point to restore sufficient frataxin levels (26), mostly by
enhancing FXN transcription. Among them, interferon
gamma (IFN- ) (27) and dyclonine (28) have been identi-
fied as encouraging candidates by drug repositioning pro-
grams. Synthetic histone deacetylase (HDAC) inhibitors
have been described to increase FXN mRNA in FRDA-
derived cells and in FRDA animal models (29,30). More
recently, synthetic nucleic acids were successfully employed
targeting GAA repeats, acting as DNA:RNA hybrids (R-
loops) inhibitors (31). Moreover, polyamide-based tran-
scription factors capable of binding GAA microsatellite
were developed (32). Interestingly, protein replacement
therapy based on Trans-Activator of Transcription (TAT)
fusion frataxin (TAT-frataxin) delivery (33), and frataxin
degradation prevention by a class of ubiquitin-competing
small molecules (34), have been recently proposed as po-
tential treatments targeting the frataxin polypeptide. Fi-
nally, an effective gene replacement strategy in the FRDA
mouse model opened new opportunities for gene therapy
(35). However, recent data has proved that prolonged over-
expression at non-physiological levels of frataxin affects cel-
lular metabolism, leading to a significant increase of ox-
idative stress and labile iron pool levels (36). These cellu-
lar alterations are similar to those observed when the gene
is partly silenced, as occurs in FRDA patients. These re-
sults suggest that any long-term therapeutic intervention
must finely tune frataxin protein levels within a physiologi-
cal range.
RNA therapeutics is of great interest for its potentials in
enlarging the range of druggable targets. The ability to ma-
nipulate gene expression for every transcript could revolu-
tionize molecular medicine with the tremendous advantage
of scalability. A large group of diseases, including FRDA,
would strongly benefit from the discovery of RNAs able
to increase gene expression and restore physiological tran-
scription and/or translation of a specific target when low
expression is pathogenic.
AS Uchl1 was previously isolated as a long non-coding
RNA (lncRNA) antisense to Ubiquitin carboxy-terminal
hydrolase L1 (Uchl1/Park5), a protein-coding mouse gene.
This sense/antisense pair presents a 5′ head-to-head con-
figuration with AS Uchl1 overlapping the sense gene for
72 nucleotides (nts) around the AUG translation initiation
codon. The overlapping region starts from +32 nts end-
ing −40 nts to AUG (A is +1) (indicated as −40/+32).
The non-overlapping part of AS Uchl1 contains embed-
ded Transposable Elements including a SINEB2 (short in-
terspersed nuclear element of B2 subfamily) sequence in
inverted orientation. Interestingly, overexpression of full
length AS Uchl1 RNA increases UCHL1 protein amounts
acting at the post-transcriptional level (37). This activity
has been proved to reside in the antisense region and in
the embedded SINEB2 element. Since this ability is shared
with several mouse antisense lncRNAs, AS Uchl1 has been
considered the representative member of a new functional
class of natural and synthetic lncRNAs, named SINEUPs,
since through the activity of an embedded inverted SINEB2
(invSINEB2) sequence they UP-regulate translation. Syn-
thetic SINEUPs require two functional domains for their
translational enhancement activity. In the non-overlapping
portion, the invSINEB2 sequence acts as Effector Domain
(ED). In the 5′, the overlapping region represents the Bind-
ing Domain (BD) and provides target selection and speci-
ficity (Figure 1B). Given knowledge of the exact Transcrip-
tion Start Site (TSS) and consequently of the 5′ untranslated
region (UTRs) of target mRNA, synthetic SINEUPs can be
designed virtually for any gene of interest to increase target
protein levels.
While the natural anatomy of the antisense sequence
found in AS Uchl1 has been considered a model for BD
design in synthetic SINEUPs, additional BD domains have
been successfully tested. Furthermore, the exclusive combi-
nation of ED and BD sequences, called miniSINEUPs, pro-
motes target protein up-regulation at post-transcriptional
level with equal efficiency proving the other regions of AS
Uchl1 dispensable for translation enhancing activity. Syn-
thetic SINEUPs and miniSINEUPs have been shown to be
effective in vitro on a wide spectrum of targets and in differ-
ent cell types (38–40). Most importantly, synthetic SINE-
UPs have been proved to correct in vivo defective gene ex-
pression with amelioration of eye and brain phenotypes in a
fish model of human Microphthalmia with Linear Skin de-
fects syndrome, a disease caused by haploinsufficient dosage
of the mitochondrial protein COX7b (41).
Here, we show that SINEUP-FXN and miniSINEUP-
FXN enhance endogenous quantities of mature frataxin
in a variety of human cell lines. SINEUP-mediated up-
regulation is even more pronounced in cells derived from
FRDA patients, where GAA expansion causes defective ex-
pression and functional insufficiency. A 2-fold increase in
frataxin quantities is measured both in fibroblasts and in
lymphoblasts, as induced by four independent SINEUPs
targeting mRNA regions located pre- and post-GAA ex-
pansion.Most importantly, in FRDA cells, SINEUPs func-
tionally rescue defects in mitochondrial aconitase activity,
one of the hallmarks of the disease. Altogether, these results
pave the way for the use of SINEUPs in RNA therapeutics
of FRDA as well as a scalable platform for haploinsufficien-
cies.
MATERIALS AND METHODS
Oligonucleotides
The complete list of oligonucleotides used for cloning,
quantitative real-time PCR experiments and lentivirus titra-
tion is included in Supplementary material (Supplementary
Table S1).
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Figure 1. Design of synthetic SINEUPs to target FXNmRNA. (A) ZENBUgenome browser view of FXN locus, showing FXN alternative TSS usage (TSS1,
TSS2 and TSS3) in FANTOM5 samples and selected libraries. FXN reference sequences and Gencode annotated transcripts are indicated. The genomic
position of the GAA triplet repeat region is highlighted (black box). (B) Schematic representation of SINEUPs functional domains. The binding domain
(BD, gray) provides SINEUP specificity and it is in antisense orientation to the sense protein-codingmRNA (TargetmRNA). The inverted SINEB2 element
(invB2) is the effector domain (ED, light blue) and confers enhancement of protein synthesis. 5′ to 3′ orientation of sense and antisense RNA molecules
is indicated. Structural elements of target mRNA are shown: 5′ untranslated region (5′UTR, white), coding sequence (CDS, black) and 3′ untranslated
region (3′UTR, white). The scheme is not drawn in scale. (C) Scheme of human FXN gene (5′-end, white) and BDs (grey) design of synthetic SINEUP-FXN
targeting the initiating M1-AUG and the M76-AUG downstream GAA expansions. The numbering refers to the position according to the methionine (i.e.
−40/+32, from 40 nucleotides upstream and to 32 nucleotides downstream the M1-AUG). The scheme is not drawn in scale.
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Constructs
SINEUP-FXN were generated using pcDNA 3.1(−)- 5′-
AS Uchl1 as backbone (37) lacking the region of overlap
(BD) to Uchl1 and retaining AS Uchl1 ED. BDs were de-
signed in antisense orientation to the most widely expressed
human FXNmRNA, targeting the first or the second AUG,
with longer or shorter overlapping region (37). Oligonu-
cleotides were annealed and cloned into recipient plas-
mid. For the plasmid-driven expression of miniSINEUP-
FXN, we constructed a DNA cassette containing the H1
RNA polymerase III promoter followed by the BDs of
SINEUP-FXN of interest, the invSINEB2 of AS Uchl1
(38), and a minimal polyadenylation signal (42). The cas-
sette was cloned into the AseI restriction site of pEGFP-
C2 vector (Clontech), with the H1 promoter oriented
in the opposite direction with respect to the CMV pro-
moter. The resulting family of plasmids is designed to con-
stitutively express a miniSINEUP of interest and the en-
hanced Green Fluorescent Protein (EGFP). All SINEUP
and miniSINEUP-containing vectors were verified by
sequencing.
Cell lines
HEK 293T/17 were obtained from ATCC® (Cat. No.
CRL-11268™) and maintained in culture with Dul-
becco’s modified Eagle’s medium (DMEM) GlutaMAX™
Supplement (Gibco by Life Technologies, Cat. No.
41090-028) supplemented with 10% fetal bovine serum
(Euroclone, Cat. No. ECS0180L) and 1% antibiotics
(penicillin/streptomycin), as suggested by the vendor.
SH-SY5Y cells were obtained from ATCC® (Cat. No.
CRL-2266™) and maintained in culture with RPMI
supplemented with GlutaMAX, 10% fetal bovine serum
not inactivated (Euroclone, Cat. No. ECS0180L) and 1%
antibiotics (penicillin/streptomycin). Human GM04078
fibroblasts, from a clinically affected FRDA patient ho-
mozygous for the GAA expansion in the FXN gene with
alleles of approximately 541 and 420 repeats, were obtained
fromNIGMSHuman Genetic Repository, Coriell Institute
for Medical Research (Camden, NJ, USA). Cells were
maintained in culture with minimum essential medium
(MEM) HEPES, GlutaMAX™ Supplement (Gibco by
Life Technologies, Cat. No. 42360024) supplemented with
15% fetal bovine serum heat inactivated (Euroclone, Cat.
No. ECS0180L), 1% non-essential amino acids and 1%
antibiotics (penicillin/streptomycin). Human GM16214
lymphoblasts from a clinically affected FRDA patient
homozygous for the GAA expansion in the FXN gene
with alleles containing approximately 700 and 600 repeats
and human GM16215 lymphoblasts from a clinically
unaffected parent with only one allele containing 830
repeats (mother of affected GM16214), were obtained from
NIGMS Human Genetic Repository, Coriell Institute for
Medical Research (Camden, NJ, USA). Both cell lines
were maintained in culture with RPMI 1640 Medium
(Euroclone ECB9006) supplemented with 15% fetal bovine
serum heat inactivated (Hyclone CHA1115L),100 U/mg
penicillin/streptomycin (Euroclone ECB3001D) and 2 mM
L-glutamine (Euroclone ECB3000D).
Transfections
HEK 293T/17 and SH-SY5Y cells were plated in six-well
plates the day before transfection at 60% confluency (4 ×
105 cells/well) and transfected with 4 g of SINEUPs or
miniSINEUPs encoding plasmids using Lipofectamine®
2000 (Invitrogen™ byLife Technologies, Cat.No. 11668019)
and following manufacturer’s instructions. Cells were col-
lected 48 hours after transfection. RNA and protein were
obtained from the same transfection in each replica.
Recombinant lentivirus production and titration
Selected miniSINEUP-FXN were cloned into a
TetON-controlled lentiviral vector, based on the pC-
CLsin.PPT.hPGK.EGFP Wpre backbone (43). Recombi-
nant third generation self-inactivating (SIN) lentiviruses
were produced and titrated as previously described (43).
Briefly, HEK 293T/17 cells were transfected using Li-
poD293™ DNA In Vitro Transfection Reagent (SignaGen
Laboratories, Cat. No. SL100668-5) with the transfer
vector plasmid plus three auxiliary plasmids (pMD2
VSV.G; pMDLg/pRRE; pRSV-REV). The conditioned
medium was collected after 24 and 48 h, filtered and
ultra-centrifuged at 50 000 RCF on a fixed angle rotor (JA
25.50 Beckmann Coulter) for 165 min at 4◦C. Viral pellets
were resuspended in DPBS without BSA (Gibco, Cat. No.
14190250). miniSINEUP-expressing lentiviral particles
were titrated by real time quantitative PCR after infection
of HEK293T/17 cells. One end-point fluorescence-titrated
lentivirus was included in each PCR titration session and
PCR-titers were converted into fluorescence-equivalent
titers throughout the study.
Infection of Human FRDA fibroblasts
At least 8.5× 105 FRDA fibroblasts were plated onto a 100
mmplate withmedium supplemented withHexadimethrine
bromide at a final concentration of 0.009 g/ml and
infected with the appropriate miniSINEUP-expressing
lentiviral vector (multiplicity of infection,MOI 10) together
with trans-activating lentiviral vector (MOI 10). Cells were
treated with doxycycline (1 g/ml) every 48 h after trans-
duction and collected after 4 days of treatment. RNA and
proteins were obtained from the same infection in each
replica.
Stable transfections of FRDA lymphoblasts
FRDAGM16214 lymphoblasts were transfected by electro-
poration as already described (13). Briefly, 15 × 106 cells
were incubated in 0.4 ml of RPMI 1640 for 10 min on
ice with 30 g of miniSINEUP-FXN constructs and the
empty vector (ctrl). After electroporation at 260 V/950 mi-
crofarads (Bio-Rad GenePulser II), cells were left 30 min
on ice and resuspended in 5 ml of complete RPMI 1640
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medium. After 4 h, live cells were recovered by Lympholyte-
Human (Cedarlane Laboratories) density gradient centrifu-
gation and re-plated. Stable transfectants were obtained
from cultures in selection medium containing 600 g /ml
G418 (Sigma) for at least 15 days.
Aconitase assays
Whole-cell extracts from GM16215 lymphoblasts,
GM16214 lymphoblasts and GM16214 lymphoblasts
stably expressing miniSINEUPs were prepared in ice-cold
CelLytic M buffer (Sigma-Aldrich) supplemented with 2
mM sodium citrate and Complete EDTA-free protease
inhibitor cocktail (Roche Diagnostic). Spectrophotometric
aconitase assays were performed at 25◦C with 100 g of
cell extracts using the BIOXYTECH Aconitase-340 Assay
(OxisResearch 21041). Spectrophotometric citrate synthase
activities were assessed at 25◦C with 10 g of cell extracts
using the Citrate Synthase Assay Kit (Sigma-Aldrich
CS0720). For the calculation of the activities, one unit
of enzyme was expressed as the amount of protein that
converted 1 mol of substrate per minute at 25◦C.
Off-targets prediction
Original sequences of FXN mRNA were aligned by using
Basic Local Alignment Search Tool (BLASTN) of Ensembl
genome browser against human cDNA database (Ensem-
ble’s annotation repository based on GRCh38 assembly).
The alignment sensitivity and scoring system were modified
based on short sequence parameters, filtered for sequence
similarity and matching consistency with the hit. Results
were further filtered to discard non-functional genes. Se-
lected off-targets are listed in Figure 5A.
Western blot
Transfected HEK 293T/17 and SH-SY5Y cells were
washed twice and collected in PBS 1X. After 5 min cen-
trifugation at 500 RCF, cell pellets were directly lysed in
300 l of Laemmli sample buffer, briefly sonicated, boiled
and loaded 10–20 l/each sample on 10–15% SDS-PAGE
gel. Infected human FRDA fibroblasts were collected in
PBS 1×. After 5-min centrifugation at 500 RCF, cell pellets
were dissolved in 100 l of Laemmli sample buffer, briefly
sonicated, boiled and loaded 20 l/each sample on 10–
15% SDS-PAGE gel. Proteins were transferred to nitrocel-
lulose membrane (Amersham™, Cat. No. GEH10600001)
for 1 h at 100 V. Membranes were blocked with 3% Bovine
SerumAlbumin (SIGMA, Cat. No. A2058) in TBST 1× so-
lution for 1 h at room temperature and then incubated with
primary antibodies. The following antibodies were used:
anti-FXN 4 g/ml (Abcam, Cat. No. 18A5DB1) overnight
at 4◦C followed by 1-h incubation at room temperature
with horseradish peroxidase-conjugated goat anti-mouse
antibody (DakoCytomation, Glostrup, Denmark), anti-
-actin-peroxidase 1:20 000 (SIGMA, Cat. No. A3854),
anti-STX1 (Santa Cruz, Cat. No. sc-12736), anti-FAM49A
(Santa Cruz, Cat. No. sc-390478), anti-GCP5 (TUBGCP5
– Santa Cruz, Cat. No. sc-365837), anti-HP1 (F-1) (CBX3
– Santa Cruz, Cat. No. sc-398562), anti-Endophilin B2 (A-
10) (SH3GLB2 – Santa Cruz, Cat. No. sc-365608), anti-
eIF4E (A-10) (Santa Cruz, Cat. No. sc-271480), anti-DISC-
1 (B-2) (Santa Cruz, Cat. No. sc-365591). Proteins of in-
terest were visualized with the Amersham™ ECL™ De-
tection Reagents (GE Healthcare by SIGMA, Cat. No.
RPN2105) or LiteAblot TURBO Extra-Sensitive Chemio-
luminescent Substrate (EuroClone, Cat. No. EMP012001).
Western blotting images were acquired using with Alliance
LD2–77WL system (Uvitec, Cambridge) and band inten-
sity was calculated using ImageJ software. FRDA lym-
phoblasts extracts were prepared in ice-cold lysis buffer (50
mMTris–HCl pH 7.5, 150 mMNaCl, 1% Igepal CA-630, 5
mM EDTA, 5 mM EGTA) supplemented with Complete
Protease Inhibitor Cocktail (Roche Diagnostics). Lysates
were clarified by centrifugation, supernatants were mixed
with 10× Laemmli sample buffer and boiled for 5 min at
95◦C. 50 g of protein extracts were resolved by 12% SDS-
PAGE gels and transferred to 0.2 M nitrocellulose mem-
brane (Trans-Blot Turbo Transfer pack, Bio-Rad). Mem-
branes were blocked with 5% non-fat dry milk in PBS/0.1%
Tween 20 and incubated with the indicated primary and
secondary antibodies: mAb anti-FXN (MAB-10876 Im-
munological Sciences), mAb anti--tubulin (clone DM1A,
Sigma-Aldrich) and secondary antibody horseradish perox-
idase (HRP)-conjugated goat anti-mouse (Thermo Fisher
Scientific). The immunoreactive bands were detected by en-
hanced chemiluminescence (ECL, GE Healthcare) and im-
aged with a ChemiDoc XRS system (Bio-Rad). Densito-
metric analysis was performed using ImageLab 5.2 software
(Bio-Rad).
RNA isolation, Reverse Transcription (RT) and quantitative
RT-PCR (qRT-PCR)
Total RNA was extracted from cell pellets using TRIzol®
Reagent (Thermo Fisher, Cat. No. 15596026) and follow-
ing manufacturer’s instructions. For HEK 293T/17, SH-
SY5Y and GM04078 fibroblasts, RNA samples were sub-
jected to TURBO™DNase (Invitrogen, Cat. No. AM1907)
treatment, to avoid plasmid DNA contamination. A total
of 1 g of RNA was subjected to retrotranscription using
iScript™cDNA Synthesis Kit (Bio-Rad, Cat. No. 1708890),
according to manufacturer’s instructions. qRT-PCR was
carried out using SYBR green fluorescent dye (iQ SYBR
Green Super Mix, Bio-Rad, Cat. No. 1708884) and an iCy-
cler IQ Real time PCR System (Bio-Rad). The reactions
were performed on diluted cDNA (1:8). Human GAPDH
was used as normalizing control in all qRT-PCR experi-
ments. For GM16214 and GM16215 lymphoblasts, cDNA
was prepared using the SuperScript VILO cDNA synthe-
sis kit (Thermo Fisher). Levels of human FXN mRNA
and miniSINEUPs RNA expression were assessed by real-
time qPCR using the StepOne Plus Instrument (Applied
Biosystems), normalized with the control genes expres-
sion. The assays were performed using the TaqMan primers
(Applied Biosystems) listed in Supplementary Table S1.
GUSB, GAPDH andACTwere used as control housekeep-
ing genes. The amplified transcripts were quantified using
the comparative Ct method and the differences in gene ex-
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pression were presented as normalized fold expression with
Ct method (44).
Statistical analysis
In all experiments, the significance of differences between
groups was evaluated by one-way ANOVA followed by
Dunnett’s post-test. Quantitative data are presented as
mean ± SEM of at least three independent experiments.
RESULTS
Synthetic SINEUP-FXN: design and screening
Since SINEUPs target the mRNA sequence around the
starting AUG, the precise knowledge of the real sites of
transcription initiation (TSS) is crucial, especially in cells
and tissues relevant for the gene of interest and its associ-
ated disease. In our experience, we have found that the anno-
tation of the reference sequence is often not representative
of the cell-type-specific usage of TSSs and of the 5′UTRs
of endogenous mRNAs. To build FXN-specific SINEUPs,
we made use of the FANTOM5 (Functional ANnoTation
Of the Mammalian genome) collection of Cap Analysis of
Gene Expression (CAGE) datasets, which represents the
widest catalogue of annotated promoters and TSSs inmam-
malian samples (45). Using the Zenbu Genome Browser
Tool for data visualization (46), we monitored TSS usage
at the human FXN locus with a specific focus on human
cells lines and tissues relevant for FRDA. Unexpectedly,
we found that the annotated reference sequences are poorly
representative of human samples. Rather, at least two ad-
ditional variants (TSS1 and TSS2) of human FXN mRNA
exist that are positioned more closely to the initiating AUG
and are supported by ‘robust’ statistical definition of pro-
moters in FANTOM5. The use of these alternative TSSs
finds further confirmation in the Gencode catalogue of
transcripts (ENST00000396366, ENST00000498653) (Fig-
ure 1A).
Based on TSS analysis, we designed FXN-specific SINE-
UPs (SINEUP-FXN) in antisense orientation to the most
widely expressed variant of human FXN mRNA. By fol-
lowing the pairing rules of the natural BD of AS Uchl1
(37), synthetic BDs were initially designed according to the
−40/+32 anatomy (38). Although FXN mRNA has a very
short 5′ UTRs, we also designed a shorter−40/+4 BD vari-
ant, as previously experimentally validated for other tar-
gets (40,47). We then generated additional SINEUP-FXN
by trimming BD sequences at both ends, following a strat-
egy previously used to optimize SINEUPs for ectopically
expressed target mRNAs but not yet tested for endoge-
nous genes. Finally, since another methionine (M76) is po-
sitioned in-frame in the second exon after the GAA-triplets
repeat, we designed three additional BDs overlapping this
sequence immediately after or across the exon I/exon II
boundary (Figure 1C). EachBDvariant was combinedwith
the ED of natural AS Uchl1 that so far represents the most
potent translational activator for SINEUPs (Figure 1B).
To screen the activity of SINEUP-FXN, we took advan-
tage of HEK 293T/17 cells which endogenously expresses
frataxin starting from the same TSSs of cells relevant for the
pathology and have been proven to support SINEUP ac-
tivity of a variety of SINEUPs targeting endogenous genes
(38) [unpublished results]. HEK 293T/17 cells were trans-
fected with SINEUP-FXN (+SINEUP) or an empty con-
trol vector (ctrl). SINEUP activity was estimated as fold
changes in protein levels in +SINEUP compared to con-
trol condition by western blotting upon -actin normaliza-
tion (Figure 2A). qRT-PCR quantification of FXNmRNA
was carried out to confirm SINEUPs act at the post-
transcriptional levels (Figure 2C). We found that SINEUP
activity varies significantly according to the overlapping re-
gion. When SINEUP-FXN were designed around the initi-
ating M1-AUG as transcribed from both TSS1 and TSS2
and included extra complementary sequences at the target
5′ end, we found that the activity was regulated by the length
of the overlap to the coding sequence (CDS). In particular,
the configuration of −40/+32 M1-AUG showed no effects
on frataxin levels (data not shown). Instead, BDs with min-
imal (−40/+4 M1-AUG) or no (−40/+0 M1-AUG) over-
lap to the CDS induced up-regulation of mature frataxin in
the range of 1.4-fold. When the overlapping region corre-
sponded exactly to the 5′UTR from TSS2, as in the case for
−14/+0 and −14/+4 M1-AUG configurations, SINEUPs
reached the highest potency (1.5- to 2-fold increase).
When BDwas designed at−40/+0 relative to the internal
in-frameM76-AUG, we measured an increment lower than
1.5-fold in frataxin protein levels relative to controls cells
(ctrl) with high variation among the replicates. This level
of up-regulation was also observed for the intron-spanning
BD (–10/–60/+0 M76-AUG) although it was not statisti-
cally significant.
In summary, we successfully designed synthetic SINE-
UPs able to increase the quantity of frataxin protein with no
effects on its mRNA levels (Figure 2C). SINEUP-mediated
up-regulation was in the range of 1.4- to 2.4-fold increase
(Figure 2B).
Synthetic miniSINEUP-FXN are active in vitro
Synthetic SINEUPs derived from natural AS Uchl1 RNA
are about 1200 nucleotides long. For their potential us-
age as RNA therapeutics, shorter functional molecules
retaining SINEUP translation enhancement activity are
needed. Therefore, four different BDs of the most effective
SINEUP-FXN, −40/+0, −14/+4, 14/+0 onM1-AUG and
−40/+4 M76-AUG, were selected and synthetized as min-
iSINEUPs, producing ≈ 250 nucleotides long transcripts
(Figure 3A). They were tested in HEK293T/17 cells as
before, proving they maintain the very same activity to-
wards endogenous frataxin (Figure 3B). These results were
also confirmed in human neuroblastoma SH-SY5Y cell
line (data not shown). Altogether, miniSINEUPs-FXN pro-
moted a protein induction consistently in the range of 1.4-
to 1.7-fold, proving they retain the same efficacy of their
full-length counterpart with the advantage of being shorter
(Figure 3C).
Validation of BD specificity and analysis of off-targets
SINEUPs and miniSINEUPs specificity for the target is
guaranteed by the antisense sequence complementarity be-
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Figure 2. Synthetic SINEUPs increase quantities of endogenous frataxin in vitro in human cells. (A-D) HEK 293T/17 cells were transfected with SINEUP-
FXN variants and empty vector (ctrl) and harvested 48 hours post-transfection. (A)Whole cell lysates were analysed by western blotting with anti-FXN and
anti--actin antibodies. One representative experiment is shown. First, FXN band intensity was normalized to the relative -actin band. Then, fold change
values were calculated normalizing to control cells (ctrl). SINEUP-FXN-transfected cells showed increased levels of endogenous FXN protein. (B) Average
fold change of FXNprotein levels. Columns represent mean± S.E.M. of n≥ 4 independent experiments; ns,P> 0.05; *P< 0.05; **P< 0.01; ***P< 0.001;
****P< 0.0001 (one-way ANOVA followed by Dunnett’s post-test). (C, D) The real-time RT-PCR analysis of FXNmRNA and SINEUPRNA expression
in transfected cells. Columns represent mean ± S.E.M. of n≥ 4 independent experiments. Variation in both target and SINEUPmRNA expression among
samples are not statistically significant (one-way ANOVA followed by Dunnett’s post-test). (C) FXN transcripts were quantified, using human GAPDH
(hGAPDH) expression as the internal control. The FXN/hGAPDH ratio for the ctrl sample was set as a baseline value to which all transcripts levels were
normalized. Unchanged FXNmRNA levels are shown, thereby confirming FXN increased protein synthesis at the post-transcriptional level. (D) SINEUP
transcripts were quantified, using the hGAPDH expression as the internal control. The SINEUP/hGAPDH ratio for −40/+4 M1-AUG sample was set
as a baseline value to which all transcripts levels were normalized.
D
ow
nloaded from
 https://academ
ic.oup.com
/nar/article-abstract/doi/10.1093/nar/gkz798/5580914/ by guest on 06 O
ctober 2019
8 Nucleic Acids Research, 2019
Figure 3. Synthetic miniSINEUPs increase endogenous FXN protein expression in human cells. (A) Scheme of human FXN gene (5′-end) and BDs anatomy
of tested syntheticminiSINEUP-FXNs targeting the initiatingM1-AUG and theM76-AUG downstreamGAA expansions. (B-E) HEK 293T/17 cells were
transfected with miniSINEUP-FXN variants (−40/+0; −14/+0 and −14/+4 M1-AUG or −40/+4 M76-AUG) and empty vector (ctrl) and harvested 48
hours post-transfection. (B)Whole cell lysates were analysed bywestern blotting with anti-FXNand anti--actin antibodies. One representative experiment
is shown. First, FXN band intensity was normalized to the relative -actin band. Then, fold change values were calculated normalizing to control cells
(ctrl). miniSINEUP-FXN-transfected cells showed increased levels of endogenous FXN protein. (C) Average fold change of FXN protein levels. Columns
represent mean ± S.E.M. of n = 3 independent experiments; ns, P > 0.05; *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001 (one-way ANOVA
followed by Dunnett’s post-test). (D, E) The real-time RT-PCR analysis of FXN mRNA and miniSINEUP RNA expression in transfected cells. Columns
represent mean ± S.E.M. of n = 3 independent experiments. Variation in both target and SINEUP mRNA expression among samples are not statistically
significant (one-way ANOVA followed by Dunnett’s post-test). (D) FXN transcripts were quantified, using human GAPDH (hGAPDH) expression as the
internal control. The FXN/hGAPDH ratio for the ctrl sample was set as a baseline value to which all transcripts levels were normalized. Unchanged FXN
mRNA levels are shown, thereby confirming FXN protein amounts were increased at the post-transcriptional level. (E) miniSINEUP transcripts were
quantified, using the hGAPDH expression as the internal control. The miniSINEUP/hGAPDH ratio for −40/+0 M1-AUG sample was set as a baseline
value to which all transcripts levels were normalized.
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Figure 4. miniSINEUP-FXN activity requires the BD sequence. (A, B)
HEK 293T/17 cells were transfected with miniSINEUP-FXN −40/+0
M1-AUG, BD (deltaBD, construct lacking the overlapping region to
FXN mRNA) and with empty vector (ctrl) and harvested 48 hours post-
transfection. (A) Whole cell lysates were analysed by western blotting with
anti-FXN and anti--actin antibodies. One representative experiment is
shown. First, FXN band intensity was normalized to the relative -actin
band. Then, fold change values were calculated normalizing to control cells
(ctrl). miniSINEUP-FXN-transfected cells showed increased levels of en-
dogenous FXN protein, while BD-transfected cells showed unchanged
protein levels. (B) Average fold change of FXN protein levels. Columns
represent mean ± S.E.M. of n ≥ 4 independent experiments; ns, P > 0.05;
*P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001 (one-way ANOVA
followed by Dunnett’s post-test).
tween the mRNA and BDs. To demonstrate the depen-
dency of miniSINEUP-FXNs activity on sequence pairing,
we synthesized a miniSINEUP lacking the BD (deltaBD,
BD). As expected, no effects on FNX protein levels were
detected (Figure 4). However, the possibility of off-targets
pairing, and the subsequent up-regulation of unintended
proteins cannot be ruled out. To predict putative off-targets,
we took advantage of the Basic Local Alignment Search
Tool (BLAST) of Ensembl genome browser to align the BD
sequences to human mRNA dataset. Results were filtered
for match orientation while non-functional genes (pseudo-
genes and patch chromosomes) were removed. As listed
in Figure 5A, potential off-targets mRNAs were identi-
fied for their 100% identity to SINEUP-FNXs within the
5′UTRs of STX1B, FAM49A and CBX3 genes with length
ranging from 13 to 20 nts. All complementary sequences
were distant from the translation initiation site of the tar-
get mRNA. Unconventional positions of target binding
sites were also identified for TUBGCP5 (CDS) and for
SH3GLB2, EIF4E andDISC1 (3′UTRs). As shown in Fig-
ure 5B and Supplementary Figure S1, in the very same
lysates whereminiSINEUP-FNXs were active, no effects on
these additional targets were observed.
Synthetic miniSINEUP-FXNs rescue physiological levels of
frataxin protein in FRDA fibroblasts
FRDA-derived cells represent the most relevant cellular
model to test therapeutic strategies for patients, as they
carry the complete FXN locus together with pathogenic
GAA-triplet repeat expansions (48). AllminiSINEUP-FXN
constructs were cloned into a lentiviral expression vec-
tor (LV), in-between the doxycycline-controlled TREt pro-
moter and BGHpA to build inducible recombinant lentivi-
ral particles (LVs miniSINEUP-FXN). We took advan-
tage of LVs, paired with a constitutive rtTA2S-M2 trans-
activator, to drive delayed andTetON-controlled expression
of miniSINEUP-FXN. An additional virus, lacking min-
iSINEUP, was used as a negative control (ctrl). To optimize
induction conditions, lentiviral particles were transduced in
SH-SY5Y cells, and miniSINEUP expression and frataxin
levels were measured at different time points, following a
single or a double doxycycline induction (Supplementary
Figure S2A). We found that a single doxycycline stimula-
tion, combined with tests at 48 h, was not sufficient to trig-
ger SINEUP-mediated increase in frataxin quantities. In-
stead, a double treatment protocol was crucial to promot-
ing protein induction (Supplementary Figure S2B, C). We
then applied the double doxycycline stimulation protocol
to infected FRDA cells as a proof-of-principle that SINE-
UPs could be exploited in a pathological context. Among
available patients-derived cells, we took advantage of pri-
mary FRDA fibroblasts (GM04078) showing an interme-
diate phenotype carrying a hyper-expansion of about 541
repeats on one allele and 420 repeats on the other one. All
LVs miniSINEUPs led to an increase in frataxin quanti-
ties in the range of 1.6- to 2.1 fold (Figure 6). Importantly,
the position of SINEUP BD relative to the GAA expan-
sion and the presence of the pathological expansion itself
did not interfere with the observed protein increase in pa-
tients’ cells. Considering that GM04078 cells show reduced
levels of frataxin, averaging around 40% when compared to
age- or sex-matched healthy-derived cells (49), SINEUP ac-
tivity rescued physiological protein quantities in this FRDA
cellular model.
Synthetic miniSINEUP-FXN rescue physiological levels of
frataxin protein in FRDA lymphoblasts
The ability of miniSINEUP-FXN to up-regulate endoge-
nous frataxin levels in patient’s fibroblasts prompted us to
evaluate their therapeutic potential in a different FRDAcel-
lular model. To this purpose, we employed FRDA-derived
lymphoblasts, which carry the pathogenic expansion of
GAA repeats and show reduced levels of the protein when
compared to controls.
Frataxin-deficient lymphoblasts derived from an FRDA
patient (GM16214) were stably transfected either with the
miniSINEUP-FXN targeting the initiating AUG (−40/+0
M1-AUG) or an empty vector as the negative control (ctrl).
Following antibiotic selection, independent clonal subpop-
ulations were monitored by western blot and real-time RT-
PCR analysis (Figure 7A, C-D). Frataxin protein levels
were evaluated in whole cell extracts from different clones
and compared to untransfected lymphoblasts. As expected,
extracts from FRDA cells showed a significant deficit of
FXN protein expression averaging ∼2.3-fold when com-
pared to control lymphoblasts derived from the healthy
heterozygous patient’s mother (Figure 7B). Analysis of in-
dependent miniSINEUP clones revealed a strong rescue
of frataxin levels while negative control transfectants (ctrl)
showed no significative change. In particular, we observed
an up-regulation ranging from 1.6- to 2.9-fold when com-
pared to negative controls (Figure 7B). FXN mRNA ex-
pression was quite similar in FRDA patient cells, negative
control clones and miniSINEUP-FXN clones, confirming
SINEUPs’ post-transcriptionalmode of action (Figure 7C).
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Figure 5. miniSINEUP-FXN effects on off-targets protein expression. (A, B) Off-targets analysis. (A) Input sequences (BDs) were aligned to the complete
transcriptome as available on Ensembl. Selected off-target genes are shown. The selection was based on BDs sequence alignment length and localization
(5′, CDS or 3′ relative to the off-target mRNA). (B) Off-targets protein expression in transfected cells. HEK 293T/17 cells were transfected with empty
vector (ctrl) and miniSINEUP-FXN variants (−40/+0; −14/+0 and −14/+4M1-AUG or −40/+4M76-AUG) and harvested 48 hours post transfection.
Empty vector (ctrl) was taken as negative control. Whole cell lysates derived from experiments presented in Figure 3 were analysed by western blotting.
One representative experiment for each off-target is shown in Supplementary Figure S1. Average fold changes of both target and off-targets for each BD
are shown. First, band intensity was normalized to the relative -actin band. Then, fold change values were calculated normalizing to control cells (ctrl).
The mean FXN fold changes are plotted as the mean ± S.E.M. (n ≥ 4); ns, P > 0.05; *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001 (one-way
ANOVA followed by Dunnett’s post-test). Off-targets fold changes are plotted as the mean ± SEM (n = 3) and p values are calculated by unpaired t-test
with Welch’s correction. ns, P > 0.05. Unchanged off-targets protein levels are shown.
Next, we investigated whether a miniSINEUP-FXN target-
ing the AUG downstreamGAA expansions (−40/+4M76-
AUG) could exert the same activity in these cells. To this
purpose, we generated new stably transfected FRDA cells.
As shown in Figure 7A, B, thisminiSINEUP-FXNwas able
to increase frataxin protein levels from 1.6- to 2.0-fold. Ac-
cording to their activity at the step of translation, FXN
mRNA levels never showed significant changes (Figure 7C).
Functional rescue of a disease-associated phenotype in FRDA
patient cells
As previously reported by several studies, frataxin-deficient
cells are primarily affected by defective ISC biosynthesis.
Accordingly, insufficient frataxin levels trigger a typical loss
in the activity of aconitases, two different ISC-dependent
enzymes located in mitochondrial and cytosolic compart-
ments. To assess the functional impact of SINEUPs, aconi-
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Figure 6. Rescue of frataxin protein levels in FRDA patient-derived fibroblasts. (A-D) GM04078 cells (patients’ primary fibroblasts) were infected with
inducible lentiviral vectors driving the expression of LVminiSINEUP-FXN variants (−40/+0; −14/+0 and −14/+4M1-AUG or −40/+4M76-AUG) and
empty viral particles (ctrl), induced 48 and 96 hours post-infection and harvested 6 days post-infection. (A) Whole cell lysates were analysed by western
blotting with anti-FXN and anti--actin antibodies. One representative experiment is shown. First, FXN band intensity was normalized to the relative -
actin. Then, fold change values were calculated normalizing to control cells (ctrl). LVminiSINEUP-FXN-infected cells show increased levels of endogenous
FXN protein. (B) Average fold change of FXN protein levels. Columns represent mean ± S.E.M. of n ≥ 4 independent experiments; ns, P > 0.05; *P <
0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001 (one-way ANOVA followed by Dunnett’s post-test). (C, D) The real-time RT-PCR analysis of FXN
mRNA and miniSINEUP RNA expression in transfected cells. Columns represent mean ± S.E.M. of n≥4 independent experiments. Variation in both
target and miniSINEUP mRNA expression among samples are not statistically significant (one-way ANOVA followed by Dunnett’s post-test). (C) FXN
transcripts were quantified, using human GAPDH (hGAPDH) expression as the internal control. The FXN/hGAPDH ratio for the ctrl sample was set as
a baseline value to which all transcripts levels were normalized. Unchanged FXN mRNA levels are shown. (D) miniSINEUP transcripts were quantified,
using the hGAPDH expression as the internal control. The miniSINEUP/hGAPDH ratio for −40/+0 M1-AUG sample was set as a baseline value to
which all transcripts levels were normalized.
tase activity was chosen as a functional readout of restor-
ing frataxin physiological levels on the above-described
FRDA stable transfectants. To evaluate the status of aconi-
tases, enzyme activity was monitored in total lysates from
miniSINEUP-FXN clones and untransfected lymphoblasts
by spectrophotometric assays. Extracts from these FRDA-
derived cells exhibited a loss of aconitase activity close
to 50% when compared to healthy-derived cells from the
patient’s parent. Total aconitase activity was rescued in
FRDA lymphoblasts stably expressing miniSINEUP-FXN
targeting the initiating AUG (−40/+0 M1-AUG) while
it remained at pathological levels in control cells. Fur-
thermore, the deficit was also rescued in cells expressing
the miniSINEUP-FXN variant targeting the internal AUG
(−40/+4 M76-AUG) (Figure 8A). Measured as a control,
activity of citrate synthase, the Krebs cycle enzyme catalyz-
ing the preceding step respect to aconitase, but lacking ISC,
did not show significant fluctuations in assayed extracts
(Figure 8B). These results demonstrate the rescue of the
major disease-associated phenotype in cells derived from
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Figure 7. Rescue of frataxin protein levels in FRDA patient-derived lymphoblasts. (A-D) GM16214 cells (patients’ primary lymphoblasts) were stably trans-
fected with miniSINEUP-FXN variants and empty vector (ctrl). miniSINEUP-FXN (−40/+0 M1-AUG), miniSINEUP-FXN (−40/+4 M76-AUG) and
ctrl stable clones were obtained from at least 15 days of G418 selection. (A) Whole cell lysates were analysed by western blotting with anti-FXN and
anti--actin antibodies. Two representative experiments are shown. First, FXN band intensity was normalized to the relative -actin. Then, fold change
values were calculated normalizing to GM16214 cells. GM16214 cells expressing miniSINEUP-FXN show increased levels of endogenous FXN protein.
(B) Average fold change of FXN protein levels. Columns represent mean ± S.E.M. of n ≥ 4 independent experiments; ns, P > 0.05; *P < 0.05; **P <
0.01; ***P < 0.001; ****P < 0.0001 (one-way ANOVA followed by Dunnett’s post-test). (C, D) The real-time RT-PCR analysis of FXN mRNA and
miniSINEUP RNA expression in transfected cells. Columns represent mean ± S.E.M. of n≥4 independent experiments. Variation in both target and
miniSINEUP mRNA expression among samples are not statistically significant (one-way ANOVA followed by Dunnett’s post-test). (C) FXN transcripts
were quantified, using human GAPDH (hGAPDH) expression as the internal control. The FXN/hGAPDH ratio for the GM16214 sample was set as a
baseline value to which all transcripts levels were normalized. Unchanged FXN mRNA levels are shown. (D) miniSINEUP transcripts were quantified,
using the hGAPDH expression as the internal control. The miniSINEUP/hGAPDH ratio for −40/+0 M1-AUG sample was set as a baseline value to
which all transcripts levels were normalized.
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Figure 8. Rescue of aconitase defects in FRDA patient-derived lymphoblasts. (A, B) The effect of miniSINEUP-FXN expression on aconitase activity was
measured on whole cells lysates. GM16214 cells expressingminiSINEUP-FXN showed restored activity of endogenous aconitase as compared toGM16215
positive control. Aconitase (A) and citrate synthase (B) activities are expressed as mU/mg ratio. Citrate synthase assay is used as an internal control.
Columns represent mean ± S.E.M. (n ≥ 4) of mU/mg values; ns, P > 0.05; *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001 (one-way ANOVA
followed by Dunnett’s post-test).
an FRDA patient. Altogether, our data prove that treat-
ment with miniSINEUPs targeting frataxin achieved pro-
tein physiological levels and a consistent rescue of patho-
physiological defects in FRDA-derived cells.
DISCUSSION
FRDA is a rare genetic disorder caused by an insufficient
quantity of frataxin protein. Since its discovery in 1996, the
understanding of frataxin functions has grown rapidly (16).
However, no effective therapy is currently available to pa-
tients (50). The main root of the pathology is the impaired
transcription of the FXN gene as a result of GAA repeat ex-
pansion. Disease onset, severity, and rate of progression are
strictly dependent on the length of repeat expansion and ul-
timately frataxin levels. HomozygousGAA expansion leads
to a pronounced drop in protein levels, up to only 20–30%
compared to noncarriers healthy individuals (51,52).
During the last decade, RNA-based therapy had a burst
of interest for both the high selectivity and the potential
scalability to treat a large repertory of human diseases.
Most RNA therapeutic molecules are inhibitory RNAs
and have been developed to down-regulate the expres-
sion of pathogenic genes. Among them, some Small In-
hibitory RNAs (siRNAs) and Anti-Sense Oligonucleotides
(ASOs) are already approved for clinical use (53). On the
other hand, a large group of diseases would strongly ben-
efit from transcriptional- or translation-stimulating drugs
able to rescue physiological levels of a specific target pro-
tein (54). Recently, gene-specific transcriptional activating
RNAs (RNAa) (55) and non-degradative ASOs (56) have
been employed to increase the expression of selected genes.
In the case of frataxin, almost all investigated molecules are
currently aiming at increasing FXN transcription (57–59).
By acting at post-transcriptional levels, SINEUP technol-
ogy represents a new and alternative approach to increase
FXN expression. In addition, SINEUPs present several ad-
vantages: target gene expression is induced within the range
of 1.5- to 2.5-fold thus limiting side effects due to exag-
gerated overexpression; SINEUP enables exclusively in situ
translation enhancement avoiding ectopic protein synthesis
in the absence of the target mRNA. Importantly, SINEUPs
do not trigger any hereditable genome editing.
Given their modular structure, different synthetic
SINEUP-FXN have been designed to specifically increase
FXN translation with BDs in antisense orientation 5′
head-to-head to the most widely expressed FXN mRNA.
Starting from the anatomy of the BD of AS Uchl1, the
representative transcript of natural SINEUPs (−40/+32
M1-AUG), we screened different BDs to identify the
ones that were shorter while maintaining specificity. Each
variant was combined with the ED of AS Uchl1 that so
far represents the most potent translational activator for
SINEUPs.
In summary, we show that synthetic SINEUPs against
the endogenous mRNA of FXN are able to increase its pro-
tein synthesis. Furthermore, we demonstrate BD’s flexibil-
ity in designing them around the initiating AUG of target
mRNA as well as covering an internal in-frame methion-
ine (M76-AUG). While AUG overlap is crucial to retain
SINEUP activity when targeting over-expressed mRNAs
(40), we prove it is not required in the case of endogenous
transcripts. In addition, a BD as short as 14 nts, still con-
fers strong SINEUP activity. This is strictly dependent on
sequence homology with target mRNA since a SINEUP
molecule lacking BD is not active. Interestingly, proteins
levels of potential off-targets sharing homology with the
BDs of SINEUP-FXN remained unchanged. In the case
D
ow
nloaded from
 https://academ
ic.oup.com
/nar/article-abstract/doi/10.1093/nar/gkz798/5580914/ by guest on 06 O
ctober 2019
14 Nucleic Acids Research, 2019
of TUBGCP5, SH3GLB2, EIF4E and DISC1 this is not
surprising since target sequences are located in the non-
conventional CDS and 3′UTRs regions. On the other hand,
despite target sequences are in their 5′UTRs, no induction
was observed for STX1B, FAM49A and CBX3 proteins. In-
terestingly, the homology regions are all located far from
the AUG suggesting that this feature may be crucial for a
correct design of an active synthetic SINEUP. Further data
on SINEUPs for a large number of targets will better de-
fine the requirements for the localization of the homology
region in mRNAs.
Together with the demonstration that SINEUPs and
miniSINEUPs are the first molecules to positively regulate
frataxin at post-transcriptional level, SINEUP activity in
FRDA-derived fibroblasts and lymphoblasts was shown to
be sufficient to re-establish frataxin physiological levels with
an increase in the range of 2-fold of the amounts found in
untreated cells.
Frataxin is an activator of the ISC biosynthetic machin-
ery (18–20) and an iron-chaperone (60–62). Furthermore,
frataxin can physically interact with mitochondrial and cy-
tosolic aconitase, with the ability to protect or reactivate
the enzyme’s cofactor (62,63). Accordingly, the rescue of
aconitase defects has been associated with a therapeutic in-
crease of frataxin levels in cellular and animal models of
FRDA (30,64–66). It was therefore important to prove that
the increase of frataxin protein mediated by miniSINEUPs
was able to rescue the activity of ISC-dependent enzymes to
physiological levels in patient’s lymphoblasts.
A great effort is undergoing on the optimization of ad-
vanced carrier nanoparticles and/or new-generations of
adenoviral-associated vectors (AAV) to meet the specific
challenges of reaching the central nervous system (CNS).
Furthermore, chemically-modified nucleic acid-based drugs
can be directly delivered into the brain by intrathecal injec-
tion. Thus, among others, a modified ASO targeting ISS-
N1 (Intronic Splicing Silencer N1) has been successfully ad-
ministrated to the human CNS by intrathecal injection (67)
and it has been recently approved by Food and Drug Ad-
ministration (FDA) for the treatment of spinal muscular
atrophy.
Two different strategies can be envisioned for the deliv-
ery of SINEUPs in vivo. By taking advantage of an appro-
priate serotype of AAV and a strong promoter, SINEUP
RNA can be expressed in the brain upon stereotaxic AAV
injection. On the other hand, chemically-modified SINE-
UPs could be delivered intrathecally. In this case, a crucial
limiting factor concerns an excessive length of the molecule
so that cells’ entry is inefficient (68). To confront these re-
quirements,miniSINEUP-FXNswere shown to be as active
as the longer SINEUP-FXNs shortening SINEUP RNA to
less than 250 nts (38). Chemical footprinting of invSINEB2
has recently identified several structural regions that are re-
quired for the ability ofASUchl1 to increase translation, in-
cluding a short terminal stem-loop hairpin structure (SL1)
as key structural determinant (69). Therefore, it is tempting
to speculate that shorter active EDs could be designed based
on structural data. The combination of 14 nts long BD
with fragmented EDs may lead to active antisense SINE-
UPs (ASO-SINEUP) short enough for chemical synthesis
and delivery in vivo.
In conclusion, we provide strong evidence that synthetic
SINEUPs enhance endogenous protein expression to the
physiological range in a cellular model of a monogenic dis-
ease. Their ability to revert pathophysiological phenotypes
in human patients’ cells warrants the pre-clinical evaluation
of a SINEUP-based therapy to treat FRDA.More broadly,
these evidences support that synthetic SINEUPs represent
a scalable platform to treat haploinsufficiency disorders.
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